DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Zhu AX, Finn RS, Edeline J. , et al; KEYNOTE-224 investigators.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol 2018;
19 (07) 940-952
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.